慢性丙型肝炎特异性靶向治疗药物的研究进展
摘要
慢性丙型肝炎是最常见的慢性肝病之一。全球大约有1．7亿人感染丙型肝炎，其中15％的患者发展为肝硬化。
近年来丙型肝炎的抗病毒治疗进展不断深入，治疗药物也不断增加。除了干扰素-α联合利巴韦林抗病毒治疗，针对丙型肝炎病毒（HCV）特异性靶向治疗药物也不断出现。
出处
《肝脏》
2008年第1期81-82,共2页
Chinese Hepatology
参考文献15
-
1Davis GL.New therapies:oral inhibitors and immune modulators.Clin Liver Dis,2006,10:865-880.
-
2De Francesco R,Migliaccio G.Challenges and successes in developing new therapies for hepatitis C.Nature,2005,436:953-960.
-
3Lindenbach BD,Rice CM.Unraveling hepatitis C virus replication from genome to function.Nature,2005,436:939-945.
-
4Hinrichsen H,Benahmou Y,Wedemeyer H,et al.HCV protease inhibitor-BILN 2061:can STAT-C drugs be designed that are equally effective across genotypes?Gastroenterology,2004,127:1347.
-
5Reiser M,Hinrichsen H,Benhamou Y,et al.Antiviral efficacy of NS3-serine protease inhibitor BILN一2061 in patients with chronic genotype 2 and 3 hepatitis C.Hepatology,2005,41:832-835.
-
6Forestier N,Weegink CJ,Purdy S,et al.Current status of subjects receiving peg-interferon-alfa-2A(PEG-INF)and ribavirin (RBV)after a 14-day study of the hepatitis C protease inhibitor telaprevir(VX-950),with PEG.Hepatology,2006.44:614A-615A.
-
7Rodriguez-Torez M,Lawitz E,Muir A.et al.Current status of subjects receiving peg-interferon alpha 2-a and ribavirin follow-on therapy alter 28 day treatment with the hepatitis C protease inhibitor teleprevir,PEG-IFN and RBV.Hepatology.2006,44:532A.
-
8McHutchison JG,Everson GT,Gordon S,Jacobson I.Results of an interim analysis of a phase 2 study of telaprevir(VX-950) with peg-interferon alfa-2a and ribavirin in previously untreated subjects with hepatitis C.J Hepatol,2007,46:S296.
-
9Zeuzem S,Sarrazin C,Rouzier R,et al.Anti-viral activity of SCH 503034,a HCV protease inhibitor,administered as monotherapy in hepatitis C genotype-1 patients refractory to pegylated interferon (PEG-IFN-alfa).Hepatology,2005,42:233A.
-
10Sarrazin C,Rouzier R,Wagner F,et al.SCH 503034,A novel hepatitis C virus protease inhibitor,plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology, 2007, 132:1270-1278.
-
1贝前列素治疗肺动脉高压的研究进展[J].今日药学,2009,19(3):3-3.
-
2武瑜,王雪梅,张国建.生物制剂靶向治疗类风湿关节炎的研究进展[J].医学综述,2015,21(9):1540-1543. 被引量：9
-
3卢俊阳,高秉仁.MicroRNA在靶向治疗缺血性心脏病中的研究进展[J].现代生物医学进展,2013,13(3):570-572.
-
4贾卫滨.特发性肺动脉高压临床特点及诊疗现状[J].心电与循环,2014,33(6):457-461.
-
5秦绪珍,李永哲.专家答疑[J].中华检验医学杂志,2007,30(10):1089-1089.
-
6肺癌个体化治疗迈出实际步伐——关注第九个“国际肺癌关注月”[J].中国处方药,2009(12):44-44.
-
7奚群英,柳志红.肺动脉高压患者的预后评估[J].心血管病学进展,2013,34(6):744-748. 被引量：3
-
8贾卫滨.根据基层医院条件，进行肺动脉高压的合理化治疗[J].中国社区医师,2013(5):7-8.
-
9Rigopoulou E.I.,Georgiadou S.P.,Barbanis S.,Dalekos G.N.,郝筱倩.阑尾切除术与原发性胆汁性肝硬化无关[J].世界核心医学期刊文摘（胃肠病学分册）,2006,0(11):49-50.
-
10陈开革,黎石宝.肺炎支原体感染研究新进展[J].中国病原生物学杂志,2013,8(5):473-475. 被引量：13
